53984-81-9

Basic information

• Product Name: 2-bromo-N-(2,6-dimethylphenyl)butanamide
• Synonyms: 2-bromo-N-(2,6-dimethylphenyl)butanamide
• CAS NO: 53984-81-9
• Molecular Formula: C₁₂H₁₆BrNO
• Molecular Weight: 270.16554
• Mol File: 53984-81-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-bromo-N-(2,6-dimethylphenyl)butanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-N-(2,6-dimethylphenyl)butanamide(53984-81-9)
• EPA Substance Registry System: 2-bromo-N-(2,6-dimethylphenyl)butanamide(53984-81-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 53984-81-9(Hazardous Substances Data)

Usage

Description

2-bromo-N-(2,6-dimethylphenyl)butanamide is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its bromine atom and the presence of a butanamide group attached to a 2,6-dimethylphenyl ring, which contributes to its reactivity and potential applications in the chemical and pharmaceutical industries.

Uses

Used in Pharmaceutical Synthesis:
2-bromo-N-(2,6-dimethylphenyl)butanamide is used as a reagent for the synthesis of arylhexamethyleniminoacetamides, which possess potential local anesthetic activity. Its unique structure allows it to be a valuable component in the development of new anesthetic agents.
Used in the Synthesis of Etidocaine:
2-bromo-N-(2,6-dimethylphenyl)butanamide is also a useful synthetic intermediate in the production of Etidocaine (E932700, HCl), a local anesthetic drug. Its role in the synthesis process is crucial for the development of this medication, which is widely used in medical procedures to provide pain relief.

Upstream product

• 22118-12-3 2-bromobutanoyl chloride 
• 87-62-7 2,6-dimethylaniline 
• 80-58-0 2-Bromobutyric acid 

Downstream Products

• 118564-54-8 2-Azepan-1-yl-N-(2,6-dimethyl-phenyl)-butyramide 
• 59359-46-5 W₃₆₁₄₉ 

Relevant articles and documents

Inhibition of inflammatory pain and cough by a novel charged sodium channel blocker

Background and Purpose: Many pain-triggering nociceptor neurons express TRPV1 or TRPA1, cation-selective channels with large pores that enable permeation of QX-314, a cationic analogue of lidocaine. Co-application of QX-314 with TRPV1 or TRPA1 activators can silence nociceptors. In this study, we describe BW-031, a novel more potent cationic sodium channel inhibitor, and test whether its application alone can inhibit pain associated with tissue inflammation and whether this strategy can also inhibit cough. Experimental Approach: We tested the ability of BW-031 to inhibit pain in three models of tissue inflammation:- inflammation in rat paws produced by complete Freund's adjuvant or by surgical incision and a mouse ultraviolet (UV) burn model. We tested the ability of BW-031 to inhibit cough induced by inhalation of dilute citric acid in guinea pigs. Key Results: BW-031 inhibited Nav1.7 and Nav1.1 channels with approximately sixfold greater potency than QX-314 when introduced inside cells. BW-031 inhibited inflammatory pain in all three models tested, producing more effective and longer-lasting inhibition of pain than QX-314 in the mouse UV burn model. BW-031 was effective in reducing cough counts by 78%–90% when applied intratracheally under isoflurane anaesthesia or by aerosol inhalation in guinea pigs with airway inflammation produced by ovalbumin sensitization. Conclusion and Implications: BW-031 is a novel cationic sodium channel inhibitor that can be applied locally as a single agent to inhibit inflammatory pain. BW-031 can also effectively inhibit cough in a guinea pig model of citric acid-induced cough, suggesting a new clinical approach to treating cough.

Method and using tracer charged ion channel

The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.

LOCAL ANESTHETIC COMPOUNDS AND USES

Novel compounds, pharmaceutical compositions and methods are disclosed for producing local anesthesia of long-duration. The compounds of this invention are multibinding compounds that comprise from 2 to 10 ligands covalently attached to a linker or linkers, each ligand being capable of binding to a ligand binding site in a voltage-gated Na + channel to modulate the biological processes/functions thereof.